ARS Pharmaceuticals (SPRY)

Executive Summary

ARS Pharmaceuticals is a commercial-stage biopharmaceutical company pioneering needle-free epinephrine delivery with its FDA-approved product neffy® (epinephrine nasal spray) for severe allergic reactions, including anaphylaxis. Launched in late 2024, neffy addresses a significant unmet need for patients and caregivers who fear or avoid auto-injectors due to needle anxiety, offering a portable, easy-to-use alternative. The company is leveraging its intranasal platform to expand into other Type I hypersensitivity indications, such as acute urticaria flares, where needle-free treatment could similarly improve adherence and outcomes. With a strong IP portfolio and a first-mover advantage in the needle-free epinephrine market, ARS Pharma is well-positioned to capture share from traditional epinephrine auto-injectors, which represent a multi-billion-dollar global market. The company's commercial execution, including payer coverage and physician adoption, will be key to near-term revenue growth. Looking ahead, ARS Pharma has multiple value-driving catalysts. The ongoing Phase 2 trial for neffy in chronic urticaria (NCT06927999) is recruiting and may provide proof of concept for a new, larger indication. Additionally, a trial investigating neffy in allergic reactions (NCT06834165) could support label expansion or broader real-world evidence. With a conservative cash runway into 2027, the company is funded to reach these milestones. However, risks include competition from generic epinephrine injectors and potential formulation challenges in nasal delivery. Overall, ARS Pharma represents a compelling commercial-stage opportunity with a de-risked product and multiple avenues for growth.

Upcoming Catalysts (preview)

• Q3 2026Topline data from Phase 2 trial of neffy in chronic urticaria60% success
• Q2 2026Completion of neffy clinical trial in allergic reactions and potential label expansion70% success
• Q2 2026First full quarter of neffy commercial sales reporting (Q1 2026 earnings)90% success